AN2 Therapeutics, Inc. 8-K

What Happened

• AN2 Therapeutics, Inc. (ANTX) filed an 8-K on March 17, 2026 under Item 2.02 to announce its results of operations and financial condition for the fourth quarter ended December 31, 2025. The company issued a press release with those results, which is attached to the filing as Exhibit 99.1 and is incorporated by reference.

Key Details

• Filing date: March 17, 2026 (Form 8-K, Item 2.02).
• Reporting period: Quarter ended December 31, 2025 (Q4 2025).
• Press release attached as Exhibit 99.1 (text of release incorporated by reference into the 8-K).
• The filing notes (Item 9.01) that the press release and exhibits are furnished, not “filed” for purposes of Section 18 of the Exchange Act and are not to be incorporated by reference in other filings unless expressly stated.

Why It Matters

• This 8-K signals AN2 has publicly released its Q4 2025 quarterly results; investors should read Exhibit 99.1 (the press release) for revenue, net income/loss, cash position, guidance or operational updates. The legal note that the release is “furnished” (not “filed”) affects how the document can be used in future SEC filings and litigation-related contexts, but does not change the substantive financial information disclosed in the press release itself.